ArticleBMC pediatrics2026
IL-10, IL-17A, and IFN-γ as clinical early-warning indicators for severe Epstein-Barr virus-associated infectious mononucleosis in children.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to assess the predictive value of plasma interleukin-17 A (IL-17 A), interleukin-10 (IL-10), interferon-γ (IFN-γ), along with laboratory parameters and clinical manifestations, for identifying severe illness in children with Epstein-Barr virus (EBV)-induced infectious mononucleosis (IM).
methodsPeripheral blood samples were collected from 90 children diagnosed with EBV-induced IM. The patients were divided into a non-severe group (n = 66) and a severe group (n = 24). Plasma levels of IL-17 A, IL-10, and IFN-γ were measured using enzyme-linked immunosorbent assay (ELISA). Using severe EBV-IM as the outcome, the clinical characteristics, laboratory parameters, immune function markers, and expression levels of three cytokines were first compared between the two groups. Indicators with a P value of less than 0.05 in the univariable analysis were selected using stepwise regression and included in the binary logistic regression analysis. The independent risk factors identified by the regression model were used to construct a nomogram. Internal validation was performed using the bootstrap resampling method. Calibration of the model was assessed using a calibration curve, and the clinical net benefit was evaluated through decision curve analysis (DCA).
resultsBinary logistic regression analysis identified IL-10, IL-17 A, Aspartate aminotransferase (AST), Glutamyl transpeptidase (GGT), and splenomegaly as independent risk factors for severe EBV-IM (P < 0.05). A nomogram was constructed by incorporating the significant predictors from the logistic regression analysis: IL-10, IL-17 A, AST, GGT, and splenomegaly. Internal validation using the Bootstrap resampling method indicated good discriminative ability of the model. The calibration curve suggested satisfactory agreement between predicted and observed probabilities. Furthermore, DCA confirmed the favorable clinical net benefit of this predictive model.
conclusionThe nomogram incorporating IL-10, IL-17 A, AST, GGT, and splenomegaly demonstrates substantial diagnostic value for identifying severe IM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.